HEARTio is developing investigational AI software that estimates the presence and extent of coronary artery disease from the routine 10-second, 12-lead ECG that clinics already record, with no new hardware, contrast or radiation. Its coronary artery disease output has received FDA Breakthrough Device Designation and is in a pivotal study; the software is not yet cleared or approved by the FDA. [1]
The Pittsburgh company was co-founded by CEO Utkars Jain, chief science officer Adam Butchy and chief operating officer Michael Leasure, with a founding team out of the University of Pittsburgh and the Wharton School. It has completed pre-seed and seed rounds, with backers including Allegheny Health Network, Innovation Works, LifeX and the Richard King Mellon Foundation. [1]